Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIPA | P38571 | 1/20 | 0.42 |
| ▸ | JAK2 | O60674 | 1/20 | 0.38 |
| ▸ | JAK1 | P23458 | 1/20 | 0.38 |
| ▸ | TYK2 | P29597 | 1/20 | 0.38 |
| ▸ | JAK3 | P52333 | 1/20 | 0.38 |
| ▸ | MGAM | O43451 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | SI | P14410 | 1/20 | 0.38 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.38 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | CCRL2 | O00421 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24695618 | 0.87 | GAA (0.41) | LIPAJAK2JAK1TYK2JAK3 | |
| SCHEMBL25957888 | 0.86 | LIPA (0.41) | LIPAJAK2JAK1TYK2JAK3 | |
| SCHEMBL2721040 | 0.85 | — | — | |
| SCHEMBL29228545 | 0.84 | LIPA (0.51) | LIPAJAK2JAK1TYK2JAK3 | |
| SCHEMBL27692577 | 0.82 | LIPA (0.45) | LIPAMGAMGAASIMGAM2 | |
| SCHEMBL8160474 | 0.81 | LIPA (0.38) | LIPAJAK2JAK1TYK2JAK3 | |
| SCHEMBL14473403 | 0.80 | MGAM (0.41) | JAK2JAK1TYK2JAK3MGAM | |
| SCHEMBL12590379 | 0.80 | MGAM (0.41) | JAK2JAK1TYK2JAK3MGAM | |
| SCHEMBL14389978 | 0.80 | MGAM (0.44) | JAK2JAK1TYK2JAK3MGAM | |
| SCHEMBL14389976 | 0.80 | MGAM (0.44) | JAK2JAK1TYK2JAK3MGAM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111848598-B | Heterocyclic compound, application thereof and composition containing same | 健艾仕生物医药有限公司 | 2024-12-10 | — | — | CN | disclosed |
| CN-118139868-A | Orally bioavailable nucleoside analogs | 维纳拓尔斯制药公司 | 2024-06-04 | — | — | CN | disclosed |
| US-20230233593-A1 | ORALLY-BIOAVAILABLE NUCLEOSIDE ANALOGS | VenatoRx Pharmaceuticals, Inc. | 2023-07-27 | — | — | US | disclosed |
| CN-108689942-B | Nitrogen-containing bicyclic compound, and preparation method and application thereof | 广东东阳光药业有限公司 | 2023-06-09 | — | — | CN | disclosed |
| US-11638715-B2 | Orally-bioavailable nucleoside analogs | VenatoRx Pharmaceuticals, Inc. (US) | 2023-05-02 | — | — | US | disclosed |
| US-20230024722-A1 | ORALLY-BIOAVAILABLE NUCLEOSIDE ANALOGS | VenatoRx Pharmaceuticals, Inc. | 2023-01-26 | — | — | US | disclosed |
| WO-2022265964-A1 | ORALLY-BIOAVAILABLE NUCLEOSIDE ANALOGS | VenatoRx Pharmaceuticals, Inc. (US) | 2022-12-22 | — | — | WO | disclosed |
| CN-111848598-A | Heterocyclic ring-containing compound, application thereof and composition containing heterocyclic ring-containing compound | 健艾仕生物医药有限公司 | 2020-10-30 | — | — | CN | disclosed |
| WO-2020216378-A1 | HETEROCYCLIC COMPOUND, APPLICATION THEREOF, AND COMPOSITION CONTAINING SAME | 健艾仕生物医药有限公司 | 2020-10-29 | — | — | WO | disclosed |
| CN-108689942-A | Nitrogenous dicyclic compound and its preparation method and application | 广东东阳光药业有限公司 | 2018-10-23 | — | — | CN | disclosed |
| CN-106187838-B | Aryl alkynes compound and its preparation method and application | 广东东阳光药业有限公司 | 2018-05-01 | — | — | CN | disclosed |
| CN-106187838-A | Arylalkyne hydrocarbon compound and its production and use | 广东东阳光药业有限公司 | 2016-12-07 | — | — | CN | disclosed |
| WO-2009121036-A2 | SUBSTITUTED ARYL PYRIMIDINONE DERIVATIVES | NEUROGEN CORPORATION (US) | 2009-10-01 | — | — | WO | disclosed |
| WO-2009121036-A2 | SUBSTITUTED ARYL PYRIMIDINONE DERIVATIVES | NEUROGEN CORPORATION (US) | 2009-10-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230024722-A1 | ORALLY-BIOAVAILABLE NUCLEOSIDE ANALOGS | SLC29A2, SLC29A1, PNP | LIPA 1835/4885JAK2 4866/4885JAK1 4802/4885 |
| US-11638715-B2 | Orally-bioavailable nucleoside analogs | SLC29A2, SLC29A1, PNP | LIPA 1835/4885JAK2 4866/4885JAK1 4802/4885 |
| US-20230233593-A1 | ORALLY-BIOAVAILABLE NUCLEOSIDE ANALOGS | SLC29A2, SLC29A1, PNP | LIPA 1835/4885JAK2 4866/4885JAK1 4802/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.